
Comparative Evaluation of 19 Reverse Transcription Loop-Mediated Isothermal Amplification Assays for Detection of SARS-CoV-2

Yajuan Dong^{a, b ‡}, Xiuming Wu^{c ‡}, Shenwei Li^d, Renfei Lu^e, Zhenzhou Wan^f,
Jianru Qin^b, Guoying Yu^b, Xia Jin^a, Chiyu Zhang^{a, c *}

a Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China;

b College of Life Sciences, Henan Normal University, Xinxiang 453007, China

c Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of
Sciences, Shanghai 200031, China

d Shanghai International Travel Healthcare Center, Shanghai 200335, China

e Clinical Laboratory, Nantong Third Hospital Affiliated to Nantong University, Nantong
226006, China;

f Medical Laboratory of Taizhou Fourth People's Hospital, Taizhou 225300, China;

Running title: Evaluation of SARS-CoV-2 RT-LAMP assays.

*Corresponding author.

Prof. Chiyu Zhang, PhD, Pathogen Discovery and Evolution Unit, Institut Pasteur of
Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, China.

Tel: +86 21 5492 3051; E-mail address: zhangcy1999@ips.ac.cn

‡ Yajuan Dong and Xiuming Wu contributed equally to this work.

26 **Abstract**

27 Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has caused a global
28 pandemics. To facilitate the detection of SARS-CoV-2 infection, various RT-LAMP assays
29 using 19 sets of primers had been developed, but never been compared. We performed
30 comparative evaluation of the 19 sets of primers using 4 RNA standards and 29 clinical
31 samples from COVID-19 patients. Six of 15 sets of primers were firstly identified to have
32 faster amplification when tested with four RNA standards, and were further subjected to
33 parallel comparison with the remaining four primer sets using 29 clinical samples. Among
34 these 10 primer sets, Set-4 had the highest positive detection rate of SARS-CoV-2 (82.8%),
35 followed by Set-10, Set-11, Set-13 and Set-14 (75.9%), and Set-14 showed the fastest
36 amplification speed (< 8.5 minutes), followed by Set-17 (< 12.5 minutes). Based on the
37 overall detection performance, Set-4, Set-10, Set-11, Set-13, Set-14 and Set-17 that target
38 *Nsp3*, *S*, *S*, *E*, *N* and *N* gene regions of SARS-CoV-2, respectively, are determined to be
39 better than the other primer sets. Two RT-LAMP assays with the Set-14 primers in
40 combination with any one of four other primer sets (Set-4, Set-10, Set-11, and Set-13) are
41 recommended to be used in the COVID-19 surveillance.

42

43 **Keywords:** COVID-19; SARS-CoV-2; LAMP; POCT; Clinical evaluation; Time threshold
44 (Tt).

45

46 **Introduction**

47 Coronavirus disease 2019 (COVID-19), caused by the newly discovered coronavirus
48 SARS-CoV-2^{1,2}, is rapidly spreading throughout the world, posing a huge challenge to global
49 public health security. As of 1 June, 2020, it has infected over 6 million people, and resulted in
50 at least 376,320 deaths globally. In the absence of effective antiviral drugs or efficacious
51 vaccines, early diagnosis of SARS-CoV-2 infection is essential for the containment of
52 COVID-19^{3,4}, without which it is impossible to timely implement intervention and quarantine
53 measures, and difficult to track contacts in order to limit virus spread.

54 Nucleic acid testing of various approaches are widely used as the primary tool for
55 diagnosing COVID-19^{3,4}. Among them, real-time quantitative PCR (RT-qPCR) methods
56 have been set as the gold standard for laboratory confirmation of SARS-CoV-2 infection
57 because of their proven track record as being the most robust technology in molecular
58 diagnostics^{4,6}. However, the RT-qPCR assay relies on sophisticated facilities with reliable
59 supply of electricity and well-trained personnel in large general hospitals and health care
60 facilities, or government labs (such as CDC), and it is relatively time-consuming (about 1.5-2
61 hrs). These limit its capacity in point-of-care settings. Moreover, visiting a clinical setting for
62 testing increases the risk of spreading the virus. Therefore, an alternative, fast, simple, and
63 sensitive point-of-care testing (POCT) is highly needed to facilitate the detection of
64 SARS-CoV-2 infection in resource-limited settings^{3,7}.

65 Loop-mediated isothermal amplification (LAMP) is a promising POCT method with high
66 sensitivity, specificity, and rapidity, and it is easy-to-use⁸. To overcome the limitation of
67 RT-qPCR assay, a number of RT-LAMP assays using at least 19 sets of different primers had
68 been developed in the last few months for the detection of SARS-CoV-2⁹⁻¹⁹. Although these
69 assays had proven sensitive and effective for the detection of SARS-CoV-2, how do they
70 compare with each other have not been evaluated. In this study, we compared all 19 sets of

71 SARS-CoV-2-specific RT-LAMP primers using the mismatch-tolerant LAMP system that is
72 faster and more sensitive than the conventional ones^{20,21}, and screened the high-efficiency
73 RT-LAMP assays for use in the detection of field samples.

74

75 **Results**

76 **Strategy for the comparative evaluation**

77 There were 19 sets of SARS-CoV-2 RT-LAMP primers available for the evaluation.
78 Among these primers, 2 sets were designed for binding to the *Nsp3* (non-structural proteins), 5
79 for *RdRp* (RNA-dependent RNA polymerase), 2 for *E* (envelope protein) and 2 for *N*
80 (nucleocapsid protein) gene regions of SARS-CoV-2 (Fig. 1). These regions are highly
81 conserved among SARS-CoV-2 and SARS-CoV, but distinct from five other human
82 coronaviruses (MERS-CoV, OC43, 229E, NL63 and HKU1). Other 4 sets of primers were
83 dispersed throughout the genome of SARS-CoV-2. The primers binding to the same target
84 gene are adjacent to each other and cover genomic segments from 251 to 1954 bps. To
85 minimize the consumption of clinical samples, and economize experimental efforts, we
86 adopted a strategy that initiated by a preliminary evaluation of the primers binding to the four
87 major genomic regions using *in vitro*-transcribed RNA standard, and followed by a further
88 evaluation of preliminarily selected primers together with four sets of other primers using
89 clinical RNA samples (Fig. 1).

90 **Preliminary evaluation of primer sets**

91 Using 3000 copies of *in vitro*-transcribed RNA standards of four gene segments of
92 SARS-CoV-2, we assessed the amplification performance of 15 sets of RT-LAMP primers.
93 Except for Set-3 that failed in amplification, all other primer sets generated amplification
94 curves with Time threshold (Tt) of 7.5-15.9 minutes and reached the plateau phase within 20

95 minutes (Fig. 2). In particular, six sets of the primers showed faster amplification with 10
96 minutes less Tt values than other primer sets (Fig. 2), implying higher amplification
97 sensitivity. The six sets (Set-2, Set-5, Set-13, Set-14, Set-17 and Set-18) of primers contain
98 three that bind to *N* gene and another three that bind to *Nsp*, *RdRp*, and *E* genes, respectively.
99 The six sets of primers were selected for further evaluation using clinical samples together
100 with other four primer sets that bind to other genomic regions of the virus.

101 **Comparative evaluation of ten primer sets using clinical samples**

102 A total of 29 RNA samples extracted from COVID-19 patients were used at 4-fold
103 dilutions. Except for one, all 29 RNA samples were detected as being SARS-CoV-2 positive
104 by at least one of the primer sets. Nine samples were detected as positive by all ten sets of
105 primers and almost all reactions (except for one with 49.5 minutes) had Tt values of less than
106 15.1 minutes, indicating a high viral load. The primer Set-4 detected 24 positive samples,
107 showing the highest positive detection rate (82.8%), followed by Set-10, Set-11, Set-13 and
108 Set-17 that all detected 22 positive samples (75.9%) (Fig. 3A). Two primer sets, Set-1 and
109 Set-18, had the lowest positive detection rates of 44.8% and 62.1%, respectively, and thus
110 were excluded in the subsequent analyses. Comparison showed that the primer Set-14 had
111 the lowest mean Tt values of less than 8.4 minutes, followed by Set-10, Set-11 and Set-13
112 that had mean Tt values of 11.1-11.5 minutes (Fig. 3A). These four fast-amplification sets of
113 primers also have small standard deviations (SD) of 1.7-2.9, indicating that the RT-LAMP
114 with these four primer sets are relatively more stable and faster than the other 15 sets. As
115 expected, the primer Set-14 is the most efficient one that generated the fastest (the lowest Tt
116 value) and the second fastest amplification in 14 and 7 samples, followed by Set-17 which is
117 the fastest in 6 samples and second best in 9 samples, demonstrating these two primer sets
118 had the best performance.

119 Because of their relatively high positive detection rate and lower Tt values, six primer sets
120 including Set-4, Set-10, Set-11, Set-13, Set-14 and Set-17 were subjected to further pairwise
121 comparison. The comparison showed that any two sets of these primers had high
122 concordance performance (87.8-97.6%) for 41 clinical RNA samples (including 29 positive
123 and 12 negative for SARS-CoV-2) (Fig. 3B). All the six primer sets had high amplification
124 efficiency with mean Tt values of less than 12 minutes (Fig. 3B). In particular, Set-14 had
125 faster amplification than the other five sets of primers (8.3-8.4 vs. 10.5-11.2 minutes).

126 **Specificity evaluation of four optimal primer sets based on sequence alignment**

127 The specificity of these primer sets had been reported in previous studies⁹⁻¹⁹. In this
128 evaluation, all ten primer sets did not generate amplification for all 12 COVID-19 negative
129 RNA samples. To further examine the specificity of six recommended primer sets (Set-4,
130 Set-10, Set-11, Set-13, Set-14 and Set-17) to other human coronaviruses, we performed
131 sequence alignment analyses. SARS-CoV-2 shared 79.5% genomic homology with
132 SARS-CoV^{1,2}, indicating a relatively high sequence identity; but it was largely distinct from
133 MERS-CoV and other four human coronaviruses (Supplementary Fig. S1). In particular,
134 several primers of Set-4, Set-10 and Set-17 correspond to gaps or insertions of the genomes
135 of MERS-CoV and other four common human coronaviruses OC43, 229E, NL63 and HKU1.
136 These results implied that these six sets of primers were unable to bind to the genomes of
137 MERS-CoV and four common human coronaviruses, therefore more specific for
138 SARS-CoV-2. However, because of high sequence identity and the use of mismatch-tolerant
139 RT-LAMP system that allows the presence of few mismatched bases between primers and
140 templates, the SARS-CoV-2 RT-LAMP assays may generate a cross-amplification of
141 SARS-CoV.

142 **Discussion**

143 SARS-CoV-2 transmission mainly occurs in the early and progressive stages of
144 COVID-19 disease during which the patients and virus carriers have higher viral load than
145 that in recovery stage²²⁻²⁴, and are generally more infectious. To contain the spread of the
146 virus, early diagnosis is essential^{3,4}. It helps to trigger timely intervention (e.g. quarantine,
147 lockdown, and contact tracing), and facilitates to optimize clinical management. It is clear that
148 serological assays are not suitable for this purpose, because detectable antibodies always
149 appear several days after infection. Therefore, viral RNA testing is the primary method for
150 early diagnostics of COVID-19. Despite being the most robust diagnostic tests,
151 RT-qPCR-based assays are more centralized in core facilities, and they are not amenable for
152 large-scale monitoring for asymptomatic and pre-symptomatic virus carriers in point-of-care
153 settings (e.g. community and home). Therefore, community- and/or home-based nucleic acid
154 assays that allow individuals to test in the community, at home, or other point-of-care sites
155 without having to visit hospitals are convenient tools for the detection of SARS-CoV-2
156 infection by the general public^{3,7}.

157 RT-LAMP assays are such needed tools^{8,20,21}. In fact, various LAMP assays have been
158 developed that included at least 19 sets of primers targeting different genomic regions of
159 SARS-CoV-2, with reported high sensitivity of detection ranging from 0.625 to 1200 copies
160 per 25 μ L reaction⁹⁻¹⁹. However, these primers are never formally evaluated with clinical
161 samples. The sensitivity and performance of a RT-LAMP assay are mainly determined by
162 the primers set, because other components of the reaction system are optimized and stable.
163 Therefore, assessing the optimal RT-LAMP primer sets for the detection of SARS-CoV-2
164 infection are important for the selection of best assay format to use for large field screening
165 of COVID-19 patients.

166 Recently, the reaction system of RT-LAMP was further optimized to have higher
167 sensitivity and faster amplification speed, even allowing the presence of few mismatched

168 bases between primer and templates in a mismatch-tolerant version ^{20,21}. Using this new
169 version, we assessed 19 sets of SARS-CoV-2 RT-LAMP primers. Six sets of primers with
170 faster amplification speed were firstly selected from 15 sets of primers using 4 RNA
171 standards, and then tested with other 4 primer sets using 41 clinical samples. Eight sets of
172 primers showed either comparable or better performance than the other 2 sets of primers
173 (Set-1 and Set-18) as determined by positive detection rate (>69.0%). Of the 8 sets of primers,
174 six were further selected based on high positive detection rate and/or overall faster
175 amplification speed (with mean Tt of less than 13 minutes). The six primer sets are Set-4,
176 Set-10, Set-11, Set-13, Set-14 and Set-17 that correspond to *Nsp3*, *S*, *S*, *E*, *N*, and *N* genes of
177 SARS-CoV-2, respectively.

178 Among these primer sets, the *N* gene-based RT-LAMP assays (Set-14 and Set-17) had the
179 fastest amplification speed, followed by *S* and *E* gene-based assay (Set-10, Set-11 and Set-13).
180 This result suggested that the *N* gene-based RT-LAMP assay is more sensitive in detecting
181 SARS-CoV-2 than that based on other genes, consisting with results of RT-qPCR assays ⁵.
182 Interestingly, previous studies showed that the sensitivities of Set-4 and Set-11 were more
183 than 100 copies per 25 μ L reaction ^{12,14}, not much higher than our assay. In this study, both
184 primer sets generated comparable performance with highly sensitive primers Set-13 and
185 Set-14 (less than 3 copies per 25 μ L reaction) ^{16,17}. In addition, two of our previous reported
186 primers, Set-8 and Set-18, exhibited high sensitivities of 3-20 copies per 25 μ L reaction and
187 good performance in the detection of clinical samples under the mismatch-tolerant reaction
188 condition ^{9,10}, but they did not show better performance than other nine primer sets in this
189 study. A reason might be that the use of the mismatch-tolerant reaction system generally
190 improved the amplification efficiency of the primers reported by other groups ²⁰.

191 The analyzed primer sets showed high specificity in that they did not amplify any
192 SARS-CoV-2 negative clinical samples. Sequence alignment analyses further supported that

193 the six sets of optimal primers had good specificity to SARS-CoV-2, albeit they might
194 generate non-specific amplification for SARS-CoV due to a high degree of sequence identity.
195 However, given the lethal nature of both SARS-CoV-2 and SARS-CoV²⁵, a non-specific
196 positive result for SARS-CoV might also be of clinical importance.

197 Two nucleic acid assays targeting different genes are suggested to be used in the
198 detection of SARS-CoV-2 to avoid potential false-negative results⁵. Based on comparable
199 performances, any two of the six optimal primer sets (Set-4, Set-10, Set-11, Set-13, Set-14
200 and Set-17) are recommend to be used in the detection of SARS-CoV-2. However,
201 simultaneous use of Set-10 and Set-11, or Set-14 and Set-17 should be avoided because the
202 former two sets target *S* gene and the latter two sets target *N* gene. In addition, because of its
203 very fast amplification speed, Set-14 is strongly encouraged to be preferentially selected for
204 the diagnosis of COVID-19 patients. Apart from the six recommend primer sets, other primers
205 such as Set-2 and Set-5 also had good performance, and can also be used in the monitoring of
206 COVID-19 infections.

207 Another advantage of our version of the RT-LAMP assay is that the results are easily
208 visualized with a pH-sensitive indicator dye (e.g. cresol red and neutral red)²⁶. Moreover, a
209 combination of a nucleic acid extraction-free protocol and a master RT-LAMP mix containing
210 all reagents (enzymes, primers, magnesium, nucleotides, dye and additives), except for the
211 template, enables the development of a simple kit that can be used at home, or a
212 community-based diagnosis center for the detection of COVID-19 infection^{3,27}.

213 In summary, we evaluated and selected six optimal primer sets from 19 sets of
214 SARS-CoV-2 RT-LAMP primers through a comparative evaluation with clinical RNA
215 samples from COVID-19 patients. Two RT-LAMP assays with the Set-14 primers and any
216 one of the other four primer sets (Set-4, Set-10, Set-11 and Set-13) are strongly
217 recommended to be used in the COVID-19 surveillance to facilitate the early finding of

218 asymptomatic and pre-symptomatic virus carriers in clinical and point-of-care settings, and
219 the monitoring of environmental samples in the field.

220

221 **Materials and Methods**

222 **Ethics Statement**

223 The study was approved by Nantong Third Hospital Ethics Committee (E2020002: 3
224 February 2020). All experiments were performed in accordance with relevant guidelines and
225 regulations. Written informed consents were obtained from each of the involved patients.

226 **Preparation of RNA standard**

227 To prepare RNA standard, four SARS-CoV-2 genomic segments (2720-3620 nt,
228 13403-15502 nt, 25901-26700 nt and 28274-29533 nt in Wuhan-Hu-1, GenBank:
229 MN908947.3) were amplified from previously confirmed positive RNA sample with
230 T7-promoter-containing primers ([Supplementary Table S1](#)). RNA standard was generated by *in*
231 *vitro* transcription, and quantitated by Qubit® 4.0 Fluorometer (Thermo Fisher Scientific,
232 USA). Copy number of RNA standard was estimated using the formula: RNA copies/ml =
233 $[\text{RNA concentration (g/}\mu\text{L)} / (\text{nt transcript length} \times 340)] \times 6.022 \times 10^{23}$.

234 **RNA samples of COVID-19 patients**

235 A total of 29 RNA samples were obtained from COVID-19 patients described in our
236 previous studies^{9,10}. In brief, RNA was extracted from 300 μL throat swabs of COVID-19
237 patients using RNA extraction Kit (Liferiver, Shanghai) and eluted in 90 μL nuclease-free
238 water. After screening and confirmation tests, the remaining RNA samples were stored at -80
239 $^{\circ}\text{C}$. When used for RT-LAMP assays, the stored SARS-CoV-2 positive RNA samples as

240 confirmed by RT-qPCR assay were thawed and 4-fold diluted. In addition, 12 SARS-CoV-2
241 negative clinical RNA samples were used as controls. .

242 **RT-LAMP Assay**

243 To assess the performance of 19 sets of RT-LAMP primers in the detection of
244 SARS-CoV-2, an optimized mismatch-tolerant RT-LAMP method that has higher sensitivity
245 and faster amplification speed than the conventional ones was used. A 25 μ L RT-LAMP
246 reaction mixture was prepared with 1x isothermal amplification buffer, 6 mM MgSO₄, 1.4 mM
247 dNTPs, 8 units of WarmStart Bst 2.0 DNA polymerase, 7.5 units of WarmStartR RT, 0.15 unit
248 of Q5 High-Fidelity DNA Polymerase, 0.2 μ M each of primers of F3 and B3, 1.6 μ M each of
249 primers of FIP and BIP, 0.4 μ M each of loop primer LF and/or LB, and 0.4 mM SYTO 9 (Life
250 technologies, Carlsbad, CA, United States). The enzymes were all purchased from New
251 England Biolabs (Beverly, MA, United States). In general, 3 μ L of RNA standard or samples
252 were added into each RT-LAMP reaction. The reaction was run at 63 °C for 50 minutes with
253 real-time monitoring by the LightCycler 96 real-time PCR System (Roche Diagnostics,
254 Mannheim, Germany).

255

256 **Reference**

- 257 1 Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J*
258 *Med* **382**, 727-733, doi:10.1056/NEJMoa2001017 (2020).
- 259 2 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat
260 origin. *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7 (2020).
- 261 3 Udugama, B. *et al.* Diagnosing COVID-19: The Disease and Tools for Detection. *ACS Nano* **14**,
262 3822-3835, doi:10.1021/acsnano.0c02624 (2020).
- 263 4 Lo, Y. M. D. & Chiu, R. W. K. Racing Towards the Development of Diagnostics for a Novel
264 Coronavirus (2019-nCoV). *Clin Chem* **66**, 503-504, doi:10.1093/clinchem/hvaa038 (2020).
- 265 5 Chu, D. K. W. *et al.* Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an
266 Outbreak of Pneumonia. *Clin Chem* **66**, 549-555, doi:10.1093/clinchem/hvaa029 (2020).
- 267 6 Li, Y. *et al.* A mismatch-tolerant RT-quantitative PCR: application to broad-spectrum
268 detection of respiratory syncytial virus. *Biotechniques* **66**, 225-230, doi:10.2144/btn-2018-0184
269 (2019).

-
- 270 7 Nguyen, T., Duong Bang, D. & Wolff, A. 2019 Novel Coronavirus Disease (COVID-19):
271 Paving the Road for Rapid Detection and Point-of-Care Diagnostics. *Micromachines (Basel)* **11**,
272 doi:10.3390/mi11030306 (2020).
- 273 8 Notomi, T. *et al.* Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* **28**, E63,
274 doi:10.1093/nar/28.12.e63 (2000).
- 275 9 Lu, R. *et al.* Development of a Novel Reverse Transcription Loop-Mediated Isothermal
276 Amplification Method for Rapid Detection of SARS-CoV-2. *Virology Sin*,
277 doi:10.1007/s12250-020-00218-1 (2020).
- 278 10 Lu, R. *et al.* A Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method
279 for Rapid Detection of SARS-CoV-2. *Int J Mol Sci* **21**, doi:10.3390/ijms21082826 (2020).
- 280 11 Yu, L. *et al.* Rapid detection of COVID-19 coronavirus using a reverse transcriptional
281 loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. *Clin Chem*,
282 doi:10.1093/clinchem/hvaa102 (2020).
- 283 12 Yan, C. *et al.* Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse
284 transcription loop-mediated isothermal amplification assay. *Clin Microbiol Infect*,
285 doi:10.1016/j.cmi.2020.04.001 (2020).
- 286 13 Mohamed, E.-T., Haim H., B. & Jinzhao, S. *A Single and Two-Stage, Closed-Tube, Molecular Test*
287 *for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry.* (2020).
- 288 14 Park, G. S. *et al.* Development of Reverse Transcription Loop-Mediated Isothermal
289 Amplification Assays Targeting SARS-CoV-2. *J Mol Diagn*, doi:10.1016/j.jmoldx.2020.03.006
290 (2020).
- 291 15 Broughton, J. P. *et al.* Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a
292 CRISPR-based DETECTR Lateral Flow Assay. *medRxiv*, 2020.2003.2006.20032334,
293 doi:10.1101/2020.03.06.20032334 (2020).
- 294 16 Yang, W. *et al.* Rapid Detection of SARS-CoV-2 Using Reverse transcription RT-LAMP
295 method. *medRxiv*, 2020.2003.2002.20030130, doi:10.1101/2020.03.02.20030130 (2020).
- 296 17 Jiang, M. *et al.* Development and validation of a rapid single-step reverse transcriptase
297 loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for
298 reliable and high-throughput screening of COVID-19. *medRxiv*, 2020.2003.2015.20036376,
299 doi:10.1101/2020.03.15.20036376 (2020).
- 300 18 Zhang, Y. *et al.* Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using
301 Colorimetric LAMP. *medRxiv*, 2020.2002.2026.20028373, doi:10.1101/2020.02.26.20028373
302 (2020).
- 303 19 Lamb, L. E., Bartolone, S. N., Ward, E. & Chancellor, M. B. Rapid Detection of Novel
304 Coronavirus (COVID-19) by Reverse Transcription-Loop-Mediated Isothermal Amplification.
305 *medRxiv*, 2020.2002.2019.20025155, doi:10.1101/2020.02.19.20025155 (2020).
- 306 20 Zhou, Y. *et al.* A Mismatch-Tolerant Reverse Transcription Loop-Mediated Isothermal
307 Amplification Method and Its Application on Simultaneous Detection of All Four Serotype of
308 Dengue Viruses. *Front Microbiol* **10**, 1056, doi:10.3389/fmicb.2019.01056 (2019).
- 309 21 Li, Y. *et al.* A Mismatch-tolerant RT-LAMP Method for Molecular Diagnosis of Highly
310 Variable Viruses. *Bio-protocol* **9**, e3415, doi:10.21769/BioProtoc.3415 (2019).
- 311 22 Wang, W. *et al.* Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA*,
312 Online ahead of print, doi:10.1001/jama.2020.3786 (2020).
- 313 23 Zou, L. *et al.* SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N*

-
- 314 *Engl J Med* **382**, 1177-1179, doi:10.1056/NEJMc2001737 (2020).
315 24 Yu, F. *et al.* Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected
316 Patients. *Clin Infect Dis*, Online ahead of print, doi:10.1093/cid/ciaa345 (2020).
317 25 Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus
318 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the
319 Chinese Center for Disease Control and Prevention. *JAMA*, doi:10.1001/jama.2020.2648
320 (2020).
321 26 Tanner, N. A., Zhang, Y. & Evans, T. C., Jr. Visual detection of isothermal nucleic acid
322 amplification using pH-sensitive dyes. *Biotechniques* **58**, 59-68, doi:10.2144/000114253 (2015).
323 27 Nie, K. *et al.* Evaluation of a direct reverse transcription loop-mediated isothermal
324 amplification method without RNA extraction for the detection of human enterovirus 71
325 subgenotype C4 in nasopharyngeal swab specimens. *PLoS One* **7**, e52486,
326 doi:10.1371/journal.pone.0052486 (2012).

327

328 **Acknowledgments**

329 We thank the grants from the National Science and Technology Major Project of China
330 (2019YFC1200603, 2017ZX10103009-002 and 2018ZX10711001) for financial support.

331 **Author Contributions**

332 C.Z. conceived and designed the study, wrote the manuscript, and supervised the project. Y.D.
333 and X.W. performed the experiments. S.L, R.L and Z.W collected and screened clinical
334 samples. C.Z., X.W., Y.D., and J.Q. analyzed the data. C.Z., G. Y. and X. J. interpreted the
335 results. X.J. contributed to critical revision of the manuscript.

336

337 **Authors' Disclosures or Potential Conflicts of Interest**

338 The authors report no conflicts of interest in this work.

339

340 **Figure Legends**

341 **Figure 1. Genome location and evaluation strategy of 19 sets of SARS-CoV-2**
342 **RT-LAMP primers.** The location of each primer set was detailed in Table 1. SD: standard
343 deviation.

344 **Figure 2. Comparison of performance of 15 RT-LAMP assays using RNA standards.**
345 The curves of non-template control (NTC) are not shown. * The Tt values of the Set-8 were
346 obtained by another repeated comparative experiments with Set-5 and Set-9, both of which
347 showed a consistent trend, but slightly lower Tt values than those shown here.

348 **Figure 3. Comparison of performance of 10 selected RT-LAMP primer sets using 41**
349 **clinical RNA samples.** A. Positive rates and Tt values of 10 selected RT-LAMP assays. B.
350 Paired comparison of Tt values of the primers Set-4, Set-10, Set-11, Set-13, Set-14 and
351 Set-17.

352


353 **Table 1 Information of 19 sets of RT-LAMP primers for the detection of SARS-CoV-2.**

Primer sets	Primer name	Primer sequence (5'-3')	Target gene	Genomic location (nt)	Sensitivity (LOD)	Refs
S1	F3 B3 FIP BIP LF LB	CTGCACCTCATGGTCATGTT AGCTCGTCGCCTAAGTCAA GAGGGACAAGGACACCAAGTGTATGGTTGAGCTGGTAGCAGA CCAAGTGGCTTACCGCAAGTTTTAGATCGGCGCCGTAAAC CCGTACTGAATGCCTTCGAGT TTCGTAAGAACGGTAATAAAGGAGC	<i>orf1ab</i>	498-711	1200 copies/25 μ L reaction	(18)
S2	F3 B3 FIP BIP LF LB	TCCAGATGAGGATGAAGAAGA AGTCTGAACAACTGGTGTAAG AGAGCAGCAGAAGTGGCACAGGTGATTGTGAAGAAGAAGAG TCAACCTGAAGAAGAGCAAGAACTGATTGTCCTCACTGCC CTCATATTGAGTTGATGGCTCA ACAAACTGTTGGTCAACAAGAC	<i>orf1ab</i>	3043-3331	1.02 fg/25 μ L reaction	(19)
S3	F3 B3 FIP BIP LF LB	GGAATTTGGTGCCACTTC CTATTCACCTCAATAGTCTGAACA CTTGTTGACCAACAGTTTGTGACTTCAACCTGAAGAAGAGCAA CGGCAGTGAGGACAATCAGACACTGGTGTAAAGTCCATCTC ATCATCATCTAACCAATCTTCTTC TCAAACAATTGTTGAGGTTCAACC	<i>orf1ab</i>	3145-3345	100 copies/15 μ L reaction	(14)
S4	F3 B3 FIP BIP LF LB	TGCAACTAATAAAGCCACG CGTCTTCTGTATGGTAGGATT TCTGACTTCAGTACATCAAACGAATAAATACCTGGTGTATACGTTGTC GACGCGCAGGGAATGGATAATCCACTACTTCTTCA GAGACT TGTTTCAACTGGTTTTGTGCTCCA TCTTGCCTGCGAAGATCTAAAC	<i>orf1ab</i> (<i>Nsp3</i>)	6253-6446	100 copies/15 μ L reaction	(14)
S5	F3 B3 FIP BIP LF LB	TGCTTCAGTCAGCTGATG TTAAATTGTCATCTTCGTCTT TCAGTACTAGTGCCTGTGCCACAATCGTTTTAAACGGGT TCGTATACAGGGCTTTGACATCTA TCTTGAAGCGACAACAA CTGCACTTACACCGCAA GTAGCTGGTTTTGCTAAATTCC	<i>orf1ab</i>	13434-13636	7 copies/10 μ L reaction	(13)
S6	F3 B3 FIP BIP LF	GGTATGATTTGTAGAAAACCCA CAACAGGAACTCCACTACC GGCATCACAGAATTGACTGTTTTTGCATACGCCAAGTCTAGG AATGCTGGTATTGTTGGTGTACTGAGGTTTGTATGAAATCACCGAA AACAAAGCTTGGCGTACACGTTCA	<i>orf1ab</i>	13925-14140	20 copies/25 μ L reaction	(12)
S7	F3 B3 FIP BIP LF	GTTACGATGGTGGCTGTA GGCATACTTAAGATTCATTTGAG AGCCTTACCCCATTTATAAATGGAGCTAACCAAGTCATCGTCAA AATGAGTTATGAGGATCAAGATGCATTATAGTAGGGATGACATTACGT AAACCAAGCTGATTTGTCTAGGTTG	<i>orf1ab</i>	14885-15081	5 copies/25 μ L reaction	(16)

S8	F3 B3 FIP BIP LF	AAACGTAATGTCATCCCTACT GGTTTTCTACATCACTATAAA CAGT ACAGATAGAGACACCAAGCTACGCTCAAATGAATCTTAAGTATGCCA ATAGCCGCCACTAGAGGAGCCCAACCA CCATAGAATTTGC GTGCGAGCTCTATTCTTTGCACTA	<i>orf1ab</i> (<i>RdRp</i>)	15034-15274	3 copies/25 μL reaction	(9)
S9	F3 B3 FIP BIP LF LB	CCACTAGAGGAGCTACTGTA TGACAA GCTACAACACGT AGGTGAGGGTTTTCTACATCACTATA TTGGAACAAGCAAATCTATGG ATGGGTTGGGATTATCCTAAATGTGTGCGAGCAAGAACAAGTG CAGTTTTTAACATGTTGTGCCAACCC TAGAGCCATGCCTAACATGCT	<i>orf1ab</i>	15182-15387	10 copies/20 μl reaction	(11)
S10	F3 B3 FIP BIP LF LB	CTGACAAAGTTTT CAGATCCTCAG AGTACCAAAAATCCAGCCTCTT TCCCA GAGACATGTATAGCATGGAATCAACTCAGGACTTGTCTTACC TGGTACTAAGAGGTTTGATAACCCTGTAGACTTCTCAGTGGAAGCA CCAAGTAACATTGAAAAAGAAA GTCCTACCATTTAATGATGGTGTTT	S	21678-21886	NA	(14)
S11	F3 B3 FIP BIP LF LB	TCTATTGCCATACCCACA GGTGTTTTGTAATTTGTTGAC CATTCA GTTGAATCACCACAAATGTGTGTTACCACAGAAATTCTACC GTTGCAATATGGCAGTTTTGTACATTGGGTGTTTTGTCTTGTT ACTGATGTCTTGGTCATAGACACT TAAACCGTGCTTAACTGGAATAGC	S	23693-23937	200 copies/25 μl reaction	(12)
S12	F3 B3 FIP BIP LF LB	CCGACGACGACTACTAGC AGAGTAAACGTAAAAGAAGGTT CTAGCCATCCTTACTGCGCTACTCACGTAAACAATATTGCA ACCTGTCTCTCCGAAACGAATTTGTAAGCACAAGCTGATG TCGATTGTGTGCGTACTGC TGAGTACATAAGTTCGTAC	E	26191-26424	20 copies/10 μL reaction	(15)
S13	F3 B3 FIP BIP LB	AGCTGATGAGTACGAACTT TTCAGATTTTTAACA CGAGAGT ACCACGAAAGCAAGAAAAAGAAGTATTCGTTTCGGAGAGACAG TTGCTAGTTACTACTAGCCATCCTTAGGTTTTACAAGACTCACGT CTGCGCTTCGATTGTGTGCGT	E	26226-26441	2.5 copies /25 μL reaction	(16)
S14	F3 B3 FIP BIP LF LB	CCAGAATGGAGAACGCAGTG CCGTCACCACCAGAATT AGCGGTGAACCAAGACGCAGGGCGGATCAAAACAACG AATTCCTCGAGGACAAGGCGAGCTCTTCGGTAGTAGCCAA TTATTGGGTAAACCTTGGGGC TTCCAATTAACACCAATAGCAGTCC	N	28354-28569	1 copies/25 μL reaction	(17)
S15	F3 B3 FIP BIP	TGGCTACTACCGAAGAGCT TGCAGCATTGTTAGCAGGAT TCTGGCCAGTTCCTAGGTAGTCCAGACGAATTCGTGGTGG AGACGGCATCATA TGGGTTGCACGGGTGCCAATGTGATCT	N	28525-28741	120 copies/25 μL reaction	(18)

	LF	GGACTGAGATCTTTCATTTTACCGT				
	LB	ACTGAGGGAGCCTTGAATACA				
S16	F3	AGATCAATTGGCACCCG	N	28702-28914	0.625 copies/25 μL reaction	(16)
	B3	CCATTGCCAGCCATTCTAGC				
	FIP	TGCTCCCTTCTGCGTAGAAGCCAATGCTGCAATCGTGCTAC				
	BIP	GGCGGCAAGTCAAGCCTCTCCCTACTGCTGCCTGGAGTT				
	LF	GCAATGTTGTTTCCTGAGGAAGTT				
	LB	CGTAGTCGCAACAGTTAAGAAATTC				
S17	F3	GCCAAAAGGCTTCTACGCA	N	28774-28971	NA	(14)
	B3	TTGCTCTCAAGCTGGTTCAA				
	FIP	TCCCCTACTGCTGCCTGGAGGCAAGTCAAGCCTCTTCTCG				
	BIP	TCTCCTGCTAGAATGGCTGGCATCTGTCAAGCAGCAGCAAAG				
	LF	TGTTGCGACTACGTGATGAGGA				
	LB	ATGGCGGTGATGCTGCTCT				
S18	F3	GCCAAAAGGCTTCTACGCA	N	28774-28971	20 copies /25 μL reaction (118.6 copies/25 μL reaction)	(10)
	B3	TTGCTCTCAAGCTGGTTCAA				
	FIP	TCCCCTACTGCTGCCTGGAGCAGTCAAGCCTCTTCTCGTT				
	BIP	TCTCCTGCTAGAATGGCTGGCATCTGTCAAGCAGCAGCAAAG				
	LB	TGGCGGTGATGCTGCTCTT				
S19	F3	AACACAAGCTTTCGGCAG	N	29083-29311	20 copies/10 μL reaction	(15)
	B3	GAAATTTGGATCTTTGTCATCC				
	FIP	CGCATTGGCATGGAAGTCACTTTGATGGCACCTGTGTAG				
	BIP	TGCGGCAATGTTTGTAAATCAGCCAAGGAAATTTGGGGAC				
	LF	TTCCTTGTCTGATTAGTTC				
	LB	ACCTTCGGGAACGTGGTT				

354 Notes: F3/B3: outer primers; FIP/BIP: forward and backward internal primers; LF/LB:
355 forward and backward loop primers.



356

357


358

359

Figure 1. Genome location and evaluation strategy of 19 sets of SARS-CoV-2 RT-LAMP primers. The location of each primer set was detailed in Table 1.

361

362



363

364


365 **Figure 2. Comparison of performance of 15 RT-LAMP assays using RNA standards.**

366 The curves of non-template control (NTC) are not shown. * The Tt values of the Set-8 were

367 obtained by another repeated comparative experiments with Set-5 and Set-9, both of which

368 showed a consistent trend, but slightly lower Tt values than those shown here.

369



B

Primer set	Set-4	Set-10	Set-4	Set-11	Set-4	Set-13	Set-4	Set-14	Set-4	Set-17
Mean Tt (mins)	10.8	11.1	10.8	11.3	10.9	11.5	10.7	8.3	11.5	12.0
Paired positive number	21		21		22		20		21	
Concordance rate	90.2%		90.2%		95.1%		87.8%		90.2%	

Primer set	Set-10	Set-11	Set-10	Set-13	Set-10	Set-14	Set-10	Set-17	Set-11	Set-13
Mean Tt (mins)	11.1	11.3	11.1	11.4	11.1	8.4	11.1	10.7	11.3	11.4
Paired positive number	21		21		21		21		21	
Concordance rate	95.1%		95.1%		97.6%		95.1%		95.1%	

Primer set	Set-11	Set-14	Set-11	Set-17	Set-13	Set-14	Set-14	Set-17
Mean Tt (mins)	11.2	8.3	11.2	10.1	11.1	8.3	8.3	10.5
Paired positive number	20		20		20		20	
Concordance rate	92.7%		90.2%		92.7%		92.7%	

370

371

372

373

374

375

Figure 3. Comparison of performance of 10 selected RT-LAMP primer sets using 41 clinical RNA samples. A. Positive rates and Tt values of 10 selected RT-LAMP assays. B. Paired comparison of Tt values of the primers Set-4, Set-10, Set-11, Set-13, Set-14 and Set-17.